Yükleniyor... / Loading...
This observational study examines the effectiveness of treatment sequences in patients with advanced or metastatic non-small cell lung cancer who receive Lorlatinib. Patients who received Lorlatinib for at least one week under the French Expanded Access Program may take part. It is a study without an assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer \[AJCC\] classification) at time of lorlatinib initiation * Patients who received at least one week of treatment with lorlatinib as part of the French Expanded Access Program (ATU program); ATU was granted due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable. Exclusion Criteria: * Patients enrolled in a lorlatinib clinical trial